Form 10-Q
GILEAD SCIENCES INC filed this Form 10-Q on 11/06/2018
Document Outline
Entire Document (7326.8 KB)
Subdocument 1 - 10-Q - 10-Q
Page 1 - UNITED STATES
Page 2 - GILEAD SCIENCES, INC.
Page 3 - Item 1. CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
Page 4 - GILEAD SCIENCES, INC.
Page 5 - GILEAD SCIENCES, INC.
Page 6 - GILEAD SCIENCES, INC.
Page 7 - GILEAD SCIENCES, INC.
Page 8 - Recently Issued Accounting Pronouncements Not Yet Adopted
Page 9 - Product Sales
Page 10 - Product Returns
Page 11 - N/A
Page 12 - Level 2 Inputs
Page 13 - N/A
Page 14 - N/A
Page 15 - N/A
Page 16 - Acquisition
Page 17 - Gadeta B.V. (Gadeta):
Page 18 - Supplemental Disclosure of Cash Flow Information - Non-Cash Investing Activity
Page 19 - N/A
Page 20 - Litigation Related to Sofosbuvir
Page 21 - Litigation with Merck
Page 22 - European Patent Claims
Page 23 - Litigation with Generic Manufacturers
Page 24 - TAF Litigation
Page 25 - Other Matters
Page 26 - N/A
Page 27 - RESULTS OF OPERATIONS
Page 28 - Management Overview
Page 29 - Financial Highlights
Page 30 - Product sales for the nine months ended September 30, 2018
Page 31 - N/A
Page 32 - N/A
Page 33 - Cost of Goods Sold and Product Gross Margin
Page 34 - Selling, General and Administrative Expenses
Page 35 - Liquidity and Capital Resources
Page 36 - Debt and Credit Facilities
Page 37 - Off-Balance Sheet Arrangements
Page 38 - In evaluating our business, you should carefully consider the following risks in addition to the oth
Page 39 - If we fail to commercialize new products or expand the indications for existing products, our prospe
Page 40 - Yescarta, a chimeric antigen receptor (CAR) T cell therapy, represents a novel approach to cancer tr
Page 41 - Our results of operations may be adversely affected by current and potential future healthcare refor
Page 42 - Laws and regulations applicable to the health care industry could impose new obligations on us, requ
Page 43 - We have engaged in, and may in the future engage in, business acquisitions, licensing arrangements,
Page 44 - Our operations depend on compliance with complex FDA and comparable international regulations. Failu
Page 45 - We depend on relationships with other companies for sales and marketing performance, technology, dev
Page 46 - Our success depends in large part on our ability to operate without infringing upon the patents or o
Page 47 - If any of our HCV products is proven to infringe the patents of any third party, we may be required
Page 48 - Petitions for Inter Partes Review filed by Initiative for Medicines, Access Knowledge
Page 49 - Manufacturing problems, including at our third-party manufacturers and corporate partners, could cau
Page 50 - We may not be able to obtain materials or supplies necessary to conduct clinical trials or to manufa
Page 51 - Aurobindo
Page 52 - Expensive litigation and government investigations have increased our expenses which may continue to
Page 53 - If we fail to attract and retain highly qualified personnel, we may be unable to successfully develo
Page 54 - There can be no assurance that we will pay dividends or continue to repurchase stock.
Page 55 - EXHIBIT
Page 56 - Exhibit Index
Page 57 - N/A
Page 58 - N/A
Page 59 - SIGNATURES
Subdocument 2 - EX-10.28 - EXHIBIT 10.28
Page 1 - Exhibit 10.28
Page 2 - Enhanced Severance
Page 3 - Release
Page 4 - At-Will Employment
Page 5 - Qualified Termination
Subdocument 3 - EX-31.1 - CEO CERTIFICATION
Page 1 - N/A
Subdocument 4 - EX-31.2 - CFO CERTIFICATION
Page 1 - N/A
Subdocument 5 - EX-32.1 - SECTION 906 CERTIFICATIONS
Page 1 - N/A
XBRL Item - EX-101.INS - XBRL INSTANCE DOCUMENT (What's this?)
XBRL Item - EX-101.SCH - XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT (What's this?)
XBRL Item - EX-101.CAL - XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT (What's this?)
XBRL Item - EX-101.DEF - XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT (What's this?)
XBRL Item - EX-101.LAB - XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT (What's this?)
XBRL Item - EX-101.PRE - XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT (What's this?)
XBRL Viewer
NASDAQ (US Dollar)
$69.20
 Stock is Down 0.58 (0.83%)
Data as of 11/16/18 4:00 p.m. ET
Minimum 20 minute delay
Refresh Quote
Recent Webcasts
Third Quarter 2018 Gilead Sciences Earnings Conference Call

October 25, 2018 4:30 p.m. ET
Play
Gilead Sciences at the Morgan Stanley 16th Annual Global Healthcare Conference

September 12, 2018 11:05 a.m. ET
Play
Second Quarter 2018 Gilead Sciences Earnings Conference Call

July 25, 2018 2:00 p.m. PT
Play
Gilead Sciences at the Goldman Sachs 39th Annual Global Healthcare Conference

June 13, 2018 8:40 a.m. PT
Play